For instance, CDK4 and ATAD2, are known to be important in ER+ BC; CDK4 is a clinical target for the treatment of ER+ BC64,65 and ATAD2 has been characterized as a marker for poor prognosis in several types of cancers (Fig. S7). This evidence concerns the gene ATAD2 and breast cancer.